<DOC>
	<DOCNO>NCT02308553</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled phase I/II trial design characterize safety estimate efficacy nintedanib combine paclitaxel chemotherapy compare paclitaxel chemotherapy alone patient BRAF wild type metastatic melanoma previously treat taxanes kinase inhibitor .</brief_summary>
	<brief_title>Efficacy Safety Nintedanib Combined With Paclitaxel Chemotherapy Patients With BRAF wt Metastatic Melanoma</brief_title>
	<detailed_description>Study Phase I : Run-In-Phase Based acceptable safety data nintedanib monotherapy , rapid dose find conducted classical 3+3 design . Predefined dose level 150 mg ( dose level 1 ) 200 mg ( dose level 2 ) nintedanib , twice daily , weekly paclitaxel 90 mg/m2 . Study Phase II Patients advance ( unresectable Stage III IV ) BRaf V600 wild type melanoma ( n=120 ) randomize ( 1:1 ) receive either Nintedanib ( 150 200 mg BID depend result phase I ) combination paclitaxel Placebo combination paclitaxel . Total study duration per patient : approximately 12 month therapy + Follow end study All patient enrol either phase I phase II treat accord follow treatment plan : Week 1 - 24 : Chemotherapy paclitaxel combine nintedanib/placebo Week 25 - 48 : Extended monotherapy nintedanib/placebo Week 52 ( approximately 4 week last treatment dose ) : End Treatment visit Follow : After end treatment survival , disease status therapies patient assess every 3 month death , progression disease end study whichever occur first</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm , ( surgically incurable unresectable ) stage III IV , BRAF V600 wildtype metastatic cutaneous malignant melanoma . 2 . Written inform consent 3 . A minimum 1 measurable lesion accord RECIST v1.1 criterion . 4 . ECOG 01 . 5 . Adequate hematologic , renal liver function within 14 day prior initiation dosing : Hematologic : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Hemoglobin ≥ 9 g/dL ( 5.6 mmol/L ; Subjects may transfusion within 7 day screen assessment ) Platelets : ≥ 100 x 109/L Hepatic Total bilirubin : ≤ 1.0 x ULN AST ALT : ≤ 1.5 x ULN ( In case liver metastasis : 2.5 x ULN ) Renal Serum creatinine : ≤ 1.5 mg/dL ( 133 µmol/L ) , great 1.5 mg/dL : Calculated creatinine clearance : ≥ 50 mL/min 6. effective method contraception least 3 month completion nintedanib/placebo monotherapy direct physician . 7 . Men use effective method contraception treatment least 6 month completion paclitaxel treatment least 3 month completion nintedanib/placebo monotherapy direct physician . 8 . Patients must recover prior treatmentrelated toxicity NCI CTCAE ( v4.0 ) Grade 0 1 , except toxicity consider safety risk alopecia . 9 . Male female , age 18 year old 10 . Life expectancy least 3 month 1 . Prior systemic therapy taxanes kinase inhibitor . Any prior therapy metastatic disease must discontinue least 4 week prior initiation dose . 2 . Major surgery radiation therapy within 4 week start study treatment ( minor surgical procedure biopsy allow , however patient must recover ) . 3 . Known inherited predisposition bleed thrombosis therapeutic anticoagulation ( except lowdose heparin and/or heparin flush need maintenance indwell intravenous devise ) antiplatelet therapy ( except lowdose therapy acetylsalicylic acid &lt; 325mg per day ) Patients follow coagulation parameter exclude : International normalise ratio ( INR ) &gt; 2 Prothrombin time ( PT ) partial thromboplastin time ( PTT ) : &gt; 50 % deviation institutional ULN 4 . History clinically significant haemorrhagic thromboembolic event past 6 month 5 . NCI CTCAE ( V4.0 ) grade 3 hemorrhage within 4 week start study treatment . 6 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior randomization . 7 . Serious , nonhealing wound , ulcer , bone fracture . 8 . Known CNS disease : Previous Grade 2 high sensory neuropathy . History known spinal cord compression , carcinomatous meningitis , evidence active brain metastasis ( e.g . stable &lt; 4 week , adequate previous treatment radiotherapy , symptomatic , require treatment anticonvulsant ; dexamethasone therapy allow administer stable dose least one month randomization ) leptomeningeal disease screen CT MRI scan . 9 . Any follow within 6 month prior enrolment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . 10 . New York Heart Association ( NYHA ) Grade II great congestive heart failure . 11 . Ongoing cardiac dysrhythmias NCI CTCAE Version 4.0 grade ≥ 2 . 12 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . 13 . Symptomatic peripheral vascular disease . 14 . Proteinuria screen demonstrated urine dipstick proteinuria ≥ 2+ ( patient discover ≥ 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . 15 . Known hypersensitivity reaction component study treatment ( e.g . contrast medium ) severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study . 16 . Previous cancer ( unless RFS interval least 5 year ) exception surgically cure carcinoma insitu cervix basal squamous cell carcinoma skin . 17 . Known clinically uncontrolled infectious disease include HIV positivity AIDSrelated illness active chronic hepatitis C and/or B infection . 18 . Pregnancy ( absence confirm ßhCG test ) lactation period . 19 . Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule 20 . Active alcohol drug abuse 21 . Treatment investigational drug treatment another clinical trial within past four week start therapy concomitantly trial . 22 . Legal incapacity limit legal capacity 23 . Significant weight loss ( &gt; 10 % body weight ) within past 6 month prior inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>BRAF V600 wildtype</keyword>
	<keyword>cutaneous malignant melanoma</keyword>
	<keyword>nintedanib</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>kinase inhibitor</keyword>
</DOC>